Skip to main content
European Commission logo print header

Investigating the Role of the Unfolded Protein Response as a Novel Targetable Pathway in BRAF Mutant Colorectal Cancer

Ziel

BRAF mutant (MT) colorectal cancer (CRC) accounts for 10-15% of CRC and represents the subgroup with the worst overall survival. There is an urgent need to identify strategies that hit the 'Achilles Heel' in poor prognostic BRAFMT CRC. Preliminary data from the host lab have shown that BRAFMT CRC cells are vulnerable to disturbances in the Endoplasmic Reticulum (ER)-specific Unfolded Protein Response (UPR) machinery. The overall aim of the proposal is to identify whether the ER stress activator ONC201 in combination with MAPKi (MEK1/2i or BRAFi) will be a novel treatment strategy for BRAFMT CRC.

Specific objectives of the proposal are
1. Investigate the effect of ONC201 combined with MAPKi in BRAFMT CRC in vitro.
2. Investigate the in vivo effect of ONC201 with MAPKi using BRAFMT CRC syngeneic and patient derived xenograft models.
3. Assess prognostic/predictive role of ER stress proteins in CRC.

UNBRACE will go beyond the current state-of-the-art by (i) developing a novel treatment strategy targeting the biology of poor prognostic BRAFMT CRC; (ii) using relevant pre-clinical models and clinical available datasets to underpin a novel stratified solution for BRAFMT CRC with poor clinical outcome. UNBRACE adopts the concept “personalized medicine strategy” through applying a novel approach targeting BRAFMT CRC.

This fellowship will provide the researcher, through mobility, an increased set of excellent skills (e.g. molecular pathology; patient derived xenografts, 3D organoids), which will give him the opportunity to become a future leader in experimental cancer medicine.

The fellowship will result in a strong collaborative network between the host and partner institute, transfer of knowledge between academia and industry, ultimately resulting in a phase I clinical trial in BRAFMT CRC. The fellowship can form the basis to attract other scientists internationally, from other disciplines and sectors to receive training in these unique R&I skills.

Koordinator

CELL STRESS DISCOVERIES LIMITED
Netto-EU-Beitrag
€ 187 866,00
Adresse
UNIT 204, NUIG BUSINESS INNOVATION CENTRE, NEWCASTLE ROAD
Galway
Irland

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Region
Ireland Northern and Western West
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 187 866,00